Alpharetta, Ga.-based Alimera Sciences Inc. terminated an agreement under which an investment bank was to sell up to $25 million of the company's common shares.
Alimera said its financing with Solar Capital Ltd. has provided the company with enough funding to advance its Iluvien product toward profitability without the need for the so-called at-the-market equity program.
Alimera entered into a $40 million term loan agreement with Solar Capital in January.
Iluvien is an implant for treating diabetic macular edema, an eye disease affecting individuals with diabetes that could lead to severe vision loss and blindness.
